Amplia Therapeutics Ltd. (INNMF)
0.10
0.00 (0.00%)
USD |
OTCM |
Jun 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.003M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 185.7% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.29% |
Profile
| Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia. |
| URL | http://www.ampliatx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia. |
| URL | http://www.ampliatx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |